WNK2 and breast cancer: Samani et al. (2020) reported that RT, along with trastuzumab, lessened Akt and mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK) phosphorylation and boosted apoptosis compared to trastuzumab alone in breast cancer cell lines.